June 5, 2012
Malignant hyperthermia: A crisis response plan
Malignant hyperthermia (MH) is a genetic skeletal muscle disorder that is incited by anesthesia drugs including succinlycholine and inhaled anesthetic agents (Gurunluoglu et al, 2009; Hopkins, 2011; Kim et al, 2011). The disorder is particularly dangerous because it rapidly develops into a hypermetabolic state resulting in hyperpyrexia, tachycardia, and intense and unrelenting muscle contraction as well as alterations in electrolyte and acid-base balance (Kim et al, 2011).
Free Daily News
- Milestone pig kidney transplant offers hope amid ethical, safety questions
- Fitch Ratings: Hospital credit outlook improves amid stabilizing margins
- Annual Leapfrog Group awards recognize top hospitals, ASCs
- US obesity rates decline for first time in a decade
- Study: Active monitoring without surgery safe for certain low-risk DCIS patients
- Data support option to skip sentinel lymph node biopsy in early breast cancer
- Surveyed nurses, physicians likely to quit
- Costs drop, access expands for GLP-1 weight loss drugs
- Q&A: Perioperative immunotherapy advances for early-stage NSCLC
- Proposals close December 16: Present at the 2025 OR Manager Conference
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement